How to Choose Wound Dressings

A procurement-side guide to navigating a fragmented, heavily regulated, and clinically consequential product category.

---

What this is and who buys it

Wound dressings are single-use medical devices — not commodities — applied to cover, protect, absorb exudate from, and actively support the healing of acute and chronic wounds. The category splits cleanly into two tiers: traditional products (woven and non-woven gauze, simple pads, bandages) that have changed little in decades, and advanced products (polyurethane foam, hydrocolloid wafers, calcium alginate sheets, hydrogels, transparent film dressings, collagen matrices, silver-impregnated composites, and bioengineered skin substitutes) where product differentiation is real, meaningful, and priced accordingly.

The primary institutional buyers are hospital materials management and supply chain teams, wound care clinic managers, ASC administrators, and long-term care facility directors. Most procure through annual GPO contract cycles — Vizient, Premier, and HealthTrust are the dominant vehicles — but formulary refresh decisions and emergency add-on purchases happen outside those windows more often than procurement officers would like to admit. The financial and clinical stakes are substantial: over 6.5 million Americans are living with chronic wounds, and pressure injury prevention has become a Joint Commission and CMS quality metric, which means dressing selection is no longer just a supply chain question.

What makes this category challenging is precisely the breadth of clinical scenarios it must cover. A hospital formulary that works well for post-surgical incision care will be inadequate for a long-term care facility managing stage III pressure injuries, and vice versa. The procurement officer who treats all dressings as interchangeable line items will, predictably, end up with a formulary that neither clinicians nor patients can rely on.

---

Key decision factors

Wound-type matching is the foundational clinical variable, and procurement cannot responsibly be separated from it. Wound depth, exudate volume, infection status, and chronicity each point toward a different product category — applying an occlusive film dressing to a heavily exuding wound, for instance, causes maceration and healing delay rather than improvement. The TIMERS framework (Tissue, Infection/Inflammation, Moisture, Edge, Repair, Social factors) has become a widely adopted clinical-alignment tool; building it into your formulary review process gives procurement and clinical staff a shared vocabulary for justifying SKU selection.

Absorbency classification per EN 13726 is the single most important technical data point to request from vendors and is still under-used in institutional procurement. The standard defines four bands — Low (0.01–4.99 g/10 cm²), Moderate (5.00–14.99 g/10 cm²), High (15.00–24.99 g/10 cm²), and Ultra-High (≥25.00 g/10 cm²) — and vendors should be able to supply the underlying test reports, not just a marketing summary. If a rep cannot produce EN 13726 data, that absence tells you something about the product's evidence base.

FDA regulatory status is a compliance point that is easy to overlook when you're evaluating a stack of product samples, but it has become considerably more complex in recent years. Class I products — basic gauze and sponges under 21 CFR 878.4020, simple occlusive dressings — require only general controls and typically carry no 510(k) clearance requirement. Class II products — foams, hydrocolloids, alginates, absorbable synthetic dressings — require 510(k) clearance and are subject to special controls. Antimicrobial dressings containing medically significant agents (silver sulfadiazine, polymyxin B, bacitracin) are now under a proposed reclassification to Class III/PMA under 88 FR 83774 published November 30, 2023, which would require premarket approval rather than simple clearance. Any antimicrobial SKU in your current formulary warrants a verification of current marketing authorization status before your next contract cycle.

Antimicrobial resistance (AMR) risk is directly tied to that regulatory shift. The FDA's proposed rule under 88 FR 83774 explicitly separates dressings by AMR concern level: high-concern agents face proposed Class III requirements, while medium- and low-concern agents face Class II with enhanced special controls. Procurement officers should audit every antimicrobial dressing in the formulary now, identify which agents are involved, and build contingency sourcing options in case a PMA pathway creates supply disruption for any affected product.

Total cost per treatment episode is where many dressing procurement decisions go wrong, because unit price and episode cost can move in opposite directions. A traditional gauze dressing priced at under $1.00 per unit sounds economical, but if it requires two to three changes daily, the cumulative nursing labor cost — at roughly $22 or more per hour, with each dressing change taking around ten minutes — can dwarf the material cost over a week. Advanced foam dressings priced at $5–$15 per unit but changed every three to seven days frequently generate lower total episode costs on a surgical ward or wound care caseload. Build a simple cost-per-episode model into every formulary comparison; vendors with strong clinical evidence will cooperate with this exercise, and those without it will deflect.

Shelf life and sterility assurance may seem like a secondary concern, but it carries regulatory weight. FDA requires manufacturers to demonstrate continued sterility, package integrity, and device functionality across the labeled shelf life — typically two to five years for most categories. This performance data must exist in the manufacturer's technical file, and procurement officers are within their rights to request it, particularly for products stored in lower-turnover clinical areas where expiration dates are a real inventory management issue.

Formulary standardization and GPO contract coverage work together. A narrow formulary — typically three to five SKUs per exudate-level category — reduces nursing decision fatigue, concentrates purchasing volume for GPO leverage, and lowers the carrying cost of safety stock. Before evaluating any non-contract product, confirm whether it falls under an existing GPO agreement; the pricing advantage of a contracted alternative almost always outweighs marginal performance differences in the standard wound categories.

Supply chain resilience deserves more attention than it received before 2020. Roughly 29% of global wound dressing manufacturers encountered raw material shortages in polyurethane, alginate fibers, or silver compounds during 2023–2024, and institutions dependent on single-source imported dressings carried disproportionate procurement risk. When evaluating any single-source vendor for a high-volume SKU, require documentation of their supply-continuity plan or dual-source manufacturing capability as a condition of award.

---

What it costs

Dressing pricing spans four orders of magnitude — from commodity gauze to bioengineered tissue substitutes — and meaningful cost comparison requires separating list price from contracted price and both from episode cost. GPO contract pricing is not publicly verifiable and typically runs 30–60% below retail list at committed volumes; bioengineered products often carry institution-specific negotiated rates that are never disclosed publicly. Payer reimbursement also varies sharply: HCPCS A-codes govern outpatient wound care reimbursement, and formulary decisions for wound clinics and ASCs need to account for reimbursement coverage before a product is added to the list.

• Entry ($0.10–$2.00/unit, retail list): Traditional gauze, non-woven pads, simple film dressings. High-volume, low-margin; GPO pricing typically well below list but not publicly verifiable.
• Mid ($3.00–$15.00/unit, retail list): Standard polyurethane foam, hydrocolloid wafers, plain alginate sheets, film island dressings. GPO contract pricing not publicly verifiable; request itemized bids against your formulary SKUs.
• Premium ($15.00–$500+/application, retail list): Silver-impregnated antimicrobial foam and alginate (unit costs run approximately 5–7× non-antimicrobial foam equivalents), collagen matrices, and bioengineered skin substitutes. Some bioengineered products exceed $1,000 per application. Confirm HCPCS A-code reimbursement coverage before including in formulary.

---

Common use cases

The same product category can serve radically different institutional contexts, and the volume and acuity mix at your facility should drive formulary composition at least as much as product marketing does.

• Acute surgical sites (hospital/ASC): Post-operative incision management, where low-to-moderate exudate, sterile presentation, and easy removal without trauma are the dominant requirements. Film island dressings and low-absorbency foams dominate this segment.
• Pressure injury prevention and treatment (hospital/LTCF): Stage II–IV pressure injuries require moderate-to-ultra-high absorbency, antimicrobial options for colonized wounds, and products compatible with frequent repositioning protocols. Foam and alginate/CMC composites are workhorses here.
• Chronic wound management (wound care clinic/home health): Diabetic foot ulcers, venous leg ulcers, and non-healing surgical wounds require dressings that can manage variable exudate over extended treatment courses; advanced moisture-balance dressings and collagen matrices are formulary considerations.
• Burn and trauma care (hospital ED/burn unit): Partial-thickness burns and traumatic abrasions require non-adherent, antimicrobial-capable, and conformable products that can be left in place for several days without disrupting fragile granulating tissue.

---

Regulatory and compliance

The regulatory classification structure for dressings is more layered than most non-specialist procurement officers realize. Class I devices — basic gauze pads and sponges under 21 CFR 878.4020 — are subject only to general controls, meaning no premarket submission is required for most manufacturers, though FDA facility registration and adverse event reporting still apply. Class II devices, which include foams, hydrocolloids, alginates, and absorbable synthetic dressings, require 510(k) premarket notification and must comply with applicable special controls, typically performance standards and labeling requirements. When evaluating a Class II product, the 510(k) clearance number should be verifiable in the FDA 510(k) database; if a vendor cannot provide it, treat that as a material compliance concern.

The most significant recent regulatory development is the proposed reclassification of antimicrobial dressings under 88 FR 83774 (November 30, 2023). The proposed rule distinguishes products based on the AMR concern level of the active antimicrobial agent: dressings containing high-AMR-concern agents like silver sulfadiazine, bacitracin, or polymyxin B are proposed for Class III, requiring Premarket Approval rather than 510(k) clearance. Class III designation would represent a substantially higher regulatory burden and could affect product availability. Procurement officers should monitor this rulemaking actively through FDA's docket and build contingency options into the formulary for any affected antimicrobial SKUs. HIPAA does not directly regulate dressing procurement, but electronic ordering systems integrated with patient records carry the usual HIPAA security obligations for any health IT vendor in that workflow.

---

Service, training, and total cost of ownership

Unlike capital equipment, wound dressings carry no installation or preventive maintenance requirement in the traditional sense, but there are real operational costs that belong in a total cost of ownership calculation. First is clinical training: formulary changes that introduce new product categories — switching from gauze-based protocols to advanced foam/alginate pathways, for instance — require structured nursing education to prevent incorrect application, which is itself a patient safety issue. Many vendors offer clinical education support as part of their contract value proposition; verify whether this is a one-time training event or an ongoing resource before signing.

Second is inventory management. Advanced dressings have longer wear times, which means lower unit throughput and a different stocking cadence than traditional gauze. Formulary standardization matters enormously here — every additional SKU adds a bin, a reorder point, an expiry monitoring burden, and a chance for the wrong product to reach a clinician under time pressure. Work with your clinical team to map SKU count to wound-type categories rather than to vendor relationships. Shelf life for most dressings runs two to five years under manufacturer-specified storage conditions (typically room temperature, away from humidity and UV exposure); storage failures that compromise sterility create both patient risk and waste cost.

Third, for wound care clinics and ASCs operating under fee schedules, the reimbursement alignment of advanced dressings is a real financial consideration. HCPCS A-codes govern how most outpatient wound dressings are reimbursed under Medicare; a formulary that includes products without appropriate A-code coverage will generate uncompensated supply costs that erode margin on wound care episodes. Verify reimbursement eligibility at the SKU level, not the product category level, before committing to any premium product line.

---

Red flags to watch for

A vendor that presents absorbency claims purely in marketing language — "highly absorbent," "advanced moisture management" — without supplying EN 13726 test data should be treated with skepticism. That standard exists precisely to make these claims comparable across products; the absence of test data means the claim cannot be verified and the product cannot be fairly benchmarked against alternatives.

Be cautious of any antimicrobial dressing SKU that a vendor is actively promoting for formulary expansion without disclosing the pending 88 FR 83774 rulemaking and its potential impact on that product's marketing authorization. A vendor who is unaware of this regulatory development, or who minimizes its significance, is not an adequate compliance partner for your procurement team.

Unrealistically long shelf-life claims — beyond five years for most sterile wound care products — without accompanying accelerated aging and real-time stability data in the technical file are a red flag for inadequate product validation. FDA expects this data to exist; if a manufacturer cannot produce it on request, the claim may be unsupported.

Finally, single-source dependency without a documented supply-continuity plan is a supply chain risk that became concrete reality during the 2023–2024 raw material shortages. If a vendor cannot describe their backup sourcing for polyurethane foam substrates, calcium alginate fibers, or silver compounds, and you are relying on them for a high-volume formulary position, that exposure belongs in your risk register.

---

Questions to ask vendors

1. Can you provide EN 13726 absorbency test reports — not marketing summaries — for each SKU proposed for our formulary?
2. What is the FDA classification and, for Class II products, the 510(k) clearance number for each product? For antimicrobial SKUs containing silver sulfadiazine, bacitracin, or polymyxin B, what is your current regulatory status under the 88 FR 83774 proposed rulemaking?
3. What is your documented supply-continuity plan for key raw materials (polyurethane, alginate, silver compounds), and do you operate dual-source manufacturing for high-volume SKUs?
4. What GPO contract(s) cover these products, and what is your committed-volume pricing schedule? (Request itemized unit pricing against our projected annual volumes.)
5. For wound care clinic or ASC use: Which HCPCS A-codes correspond to each product, and can you confirm current Medicare reimbursement eligibility?
6. What clinical education and in-service support is included in the contract, and is that support available on an ongoing basis or limited to initial formulary onboarding?

---

Alternatives

The most consequential "buy vs. alternative" decision in dressing procurement is not between brands — it is between traditional and advanced dressings for a given wound type, and the economics frequently favor the advanced option when nursing labor is properly costed. Beyond that, the standard lease-vs-buy and new-vs-refurbished considerations that apply to capital equipment do not directly apply to consumable dressings, but several structural alternatives are worth understanding.

• GPO contract vs. direct negotiation: For most hospitals and health systems, GPO contracts (Vizient, Premier, HealthTrust) provide pricing floors that are difficult to beat on standard SKUs. Direct negotiation makes sense for non-formulary or specialty products outside GPO coverage, or for very high-volume categories where committed-volume discounts can be structured independently.
• Distributor vs. manufacturer direct: Distributor procurement consolidates invoicing and logistics but may add margin; manufacturer-direct relationships can improve pricing on high-volume SKUs but increase supply chain complexity. Many institutions use a hybrid: distributor for breadth, direct contracts for the top five to ten highest-volume SKUs.
• Formulary reduction as cost lever: The most underused cost management tool in this category is simply reducing SKU count. Standardizing to three to five products per exudate-level category, with clinical protocol support, consistently reduces total spend relative to wide-open formulary approaches because it concentrates volume and eliminates low-velocity inventory waste.
• Consignment or vendor-managed inventory (VMI): Some advanced-dressing vendors — particularly in the bioengineered and collagen matrix segment — offer VMI arrangements that shift carrying cost and expiry risk. These arrangements are worth evaluating for expensive, low-turnover specialty products, with close attention to contract terms governing ownership, returns, and substitution flexibility.

---

Sources

No external source articles were available for this guide. The regulatory references (21 CFR 878.4020, 88 FR 83774), EN 13726 absorbency classification, and GPO network names cited above are drawn from publicly available federal regulatory records and international standards documentation. Readers are encouraged to verify current regulatory status of specific products directly via the FDA 510(k) database and the FDA docket for 88 FR 83774.